| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (CCTG) IND.238 | A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity | Dr Peter Ellis | Open to recruitment | NCT03847649 |
| (Takeda) TAK-676-1002 | An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors | Dr Brandon Meyers | Suspended/On hold | NCT04420884 |
| (Bold Therapeutics) BOLD-100-001 / TRIO039 | A Phase 1b Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours | Dr Elaine McWhirter | Open to recruitment | NCT04421820 |
Find a Trial
Contact Us